5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.23▼ | 1.24▼ | 1.25▼ | 1.31▼ | 1.24▼ |
MA10 | 1.23▼ | 1.26▼ | 1.27▼ | 1.37▼ | 1.32▼ |
MA20 | 1.24▼ | 1.28▼ | 1.30▼ | 1.28▼ | 1.55▼ |
MA50 | 1.26▼ | 1.32▼ | 1.36▼ | 1.33▼ | 2.09▼ |
MA100 | 1.28▼ | 1.37▼ | 1.36▼ | 1.56▼ | 2.76▼ |
MA200 | 1.31▼ | 1.34▼ | 1.23▼ | 2.00▼ | 6.82▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | -0.005▼ | -0.007▼ | -0.001▼ | 0.008▲ |
RSI | 33.677▼ | 28.226▼ | 28.443▼ | 44.088▼ | 40.596▼ |
STOCH | 20.000 | 11.586▼ | 18.074▼ | 30.495 | 38.469 |
WILL %R | -75.000 | -90.909▼ | -92.857▼ | -82.090▼ | -66.183 |
CCI | -60.705 | -110.650▼ | -152.409▼ | -113.947▼ | -46.566 |
Thursday, June 12, 2025 08:30 AM
A month has gone by since the last earnings report for Allogene Therapeutics (ALLO). Shares have added about 52.2% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
|
Monday, June 02, 2025 12:26 PM
Allogene Therapeutics Inc. (NASDAQ:ALLO) presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma/RCC during an oral presentation at the 2025 ...
|
Sunday, June 01, 2025 07:50 AM
June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ) products for cancer ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
20/06/25 | 1.31 | 1.3292 | 1.2101 | 1.23 | 3,630,549 |
18/06/25 | 1.29 | 1.36 | 1.26 | 1.29 | 2,123,957 |
17/06/25 | 1.35 | 1.39 | 1.29 | 1.30 | 1,667,801 |
16/06/25 | 1.35 | 1.41 | 1.3204 | 1.37 | 1,764,080 |
13/06/25 | 1.35 | 1.4186 | 1.325 | 1.34 | 2,450,471 |
12/06/25 | 1.43 | 1.45 | 1.3801 | 1.40 | 2,282,726 |
11/06/25 | 1.49 | 1.50 | 1.44 | 1.45 | 2,594,726 |
10/06/25 | 1.39 | 1.505 | 1.39 | 1.47 | 2,019,331 |
09/06/25 | 1.45 | 1.50 | 1.37 | 1.41 | 2,214,437 |
06/06/25 | 1.30 | 1.47 | 1.29 | 1.42 | 3,475,881 |
|
|
||||
|
|
||||
|
|